Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8+ T cells
Background The mitogen-activated protein kinases (MAPKs) are important for T cell survival and their effector function. Mixed lineage kinase 3 (MLK3) (MAP3K11) is an upstream regulator of MAP kinases and emerging as a potential candidate for targeted cancer therapy; yet, its role in T cell survival...
Main Authors: | Sunil Kumar Singh, Navin Viswakarma, Gautam Sondarva, Rakesh Sathish Nair, Periannan Sethupathi, Matthew Dorman, Subhash C Sinha, Kent Hoskins, Gregory Thatcher, Basabi Rana, Ajay Rana |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/8/2/e000494.full |
Similar Items
-
Mitogen-Activated Protein Kinase Inhibitors and T-Cell-Dependent Immunotherapy in Cancer
by: Sandeep Kumar, et al.
Published: (2020-01-01) -
Transcription Factors in Cancer Development and Therapy
by: Kanchan Vishnoi, et al.
Published: (2020-08-01) -
HDAC3 restrains CD8-lineage genes to maintain a bi-potential state in CD4+CD8+ thymocytes for CD4-lineage commitment
by: Rachael Laura Philips, et al.
Published: (2019-01-01) -
Tag7 (PGLYRP1) Can Induce an Emergence of the CD3+CD4+CD25+CD127+ Cells with Antitumor Activity
by: T. N. Sharapova, et al.
Published: (2018-01-01) -
The order and logic of CD4 versus CD8 lineage choice and differentiation in mouse thymus
by: Mohammad M. Karimi, et al.
Published: (2021-01-01)